+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Immune Checkpoint Inhibitors for Lung Cancer Market by Products (Atezolizumab, Durvalumab, Nivolumab), Type (CTLA-4 Inhibitors, PD-1 Inhibitors, PD-L1 Inhibitors), End-Users - Forecast 2024-2030- Product Image
Global Immune Checkpoint Inhibitors for Lung Cancer Market by Products (Atezolizumab, Durvalumab, Nivolumab), Type (CTLA-4 Inhibitors, PD-1 Inhibitors, PD-L1 Inhibitors), End-Users - Forecast 2024-2030- Product Image
Sale

Global Immune Checkpoint Inhibitors for Lung Cancer Market by Products (Atezolizumab, Durvalumab, Nivolumab), Type (CTLA-4 Inhibitors, PD-1 Inhibitors, PD-L1 Inhibitors), End-Users - Forecast 2024-2030

  • PDF Icon

    Report

  • 199 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5666149
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Immune Checkpoint Inhibitors for Lung Cancer Market size was estimated at USD 1.01 billion in 2023, USD 1.15 billion in 2024, and is expected to grow at a CAGR of 14.55% to reach USD 2.62 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Immune Checkpoint Inhibitors for Lung Cancer Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Immune Checkpoint Inhibitors for Lung Cancer Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Immune Checkpoint Inhibitors for Lung Cancer Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Bayer AG, BeyondSpring Pharmaceuticals Inc., BioLineRx Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, IQVIA Inc., Jazz Pharmaceuticals PLC, Laboratory Corporation of America Holdings, Merck KGaA, Mirati Therapeutics Inc., and Ono Pharmaceutical Co., Ltd.

Market Segmentation & Coverage

This research report categorizes the Immune Checkpoint Inhibitors for Lung Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Products
    • Atezolizumab
    • Durvalumab
    • Nivolumab
    • Pembrolizumab
  • Type
    • CTLA-4 Inhibitors
    • PD-1 Inhibitors
    • PD-L1 Inhibitors
  • End-Users
    • Academic & Research Institutes
    • Hospitals
    • Pharmaceutical & Biotechnology Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Immune Checkpoint Inhibitors for Lung Cancer Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Immune Checkpoint Inhibitors for Lung Cancer Market?
  3. What are the technology trends and regulatory frameworks in the Immune Checkpoint Inhibitors for Lung Cancer Market?
  4. What is the market share of the leading vendors in the Immune Checkpoint Inhibitors for Lung Cancer Market?
  5. Which modes and strategic moves are suitable for entering the Immune Checkpoint Inhibitors for Lung Cancer Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Immune Checkpoint Inhibitors for Lung Cancer Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High prevalence of lung cancer necessitating immune checkpoint inhibitors
5.1.1.2. Government investment in cancer research and treatment
5.1.1.3. Increasing product approval by regulatory agencies
5.1.2. Restraints
5.1.2.1. Limited affordability and reimbursement for immune checkpoint inhibitor therapies
5.1.3. Opportunities
5.1.3.1. Development of promising predictive biomarkers for immune checkpoint inhibitor therapies
5.1.3.2. Combination of immune checkpoint inhibitors with other cancer therapies
5.1.4. Challenges
5.1.4.1. Lack of research standardization of checkpoint inhibitors
5.1.4.2. Possible side-effects of immune checkpoint inhibitors
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Immune Checkpoint Inhibitors for Lung Cancer Market, by Products
6.1. Introduction
6.2. Atezolizumab
6.3. Durvalumab
6.4. Nivolumab
6.5. Pembrolizumab
7. Immune Checkpoint Inhibitors for Lung Cancer Market, by Type
7.1. Introduction
7.2. CTLA-4 Inhibitors
7.3. PD-1 Inhibitors
7.4. PD-L1 Inhibitors
8. Immune Checkpoint Inhibitors for Lung Cancer Market, by End-Users
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Hospitals
8.4. Pharmaceutical & Biotechnology Companies
9. Americas Immune Checkpoint Inhibitors for Lung Cancer Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Immune Checkpoint Inhibitors for Lung Cancer Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Immune Checkpoint Inhibitors for Lung Cancer Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. AstraZeneca PLC
13.1.3. Bayer AG
13.1.4. BeyondSpring Pharmaceuticals Inc.
13.1.5. BioLineRx Ltd.
13.1.6. Bristol-Myers Squibb Company
13.1.7. F. Hoffmann-La Roche Ltd.
13.1.8. Genentech, Inc.
13.1.9. GlaxoSmithKline PLC
13.1.10. IQVIA Inc.
13.1.11. Jazz Pharmaceuticals PLC
13.1.12. Laboratory Corporation of America Holdings
13.1.13. Merck KGaA
13.1.14. Mirati Therapeutics Inc.
13.1.15. Ono Pharmaceutical Co., Ltd.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET RESEARCH PROCESS
FIGURE 2. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2022 VS 2030
FIGURE 3. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET DYNAMICS
FIGURE 7. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2022 VS 2030 (%)
FIGURE 8. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 10. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2022 VS 2030 (%)
FIGURE 12. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 14. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 16. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 22. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 6. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 11. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 15. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 28. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 29. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 31. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 32. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 45. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 46. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 48. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 49. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 54. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 55. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 72. THAILAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 73. THAILAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. THAILAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 83. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 85. EGYPT IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 86. EGYPT IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. EGYPT IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 88. FINLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 89. FINLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. FINLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 91. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 92. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 93. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 94. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 95. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 100. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 101. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 109. NORWAY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 110. NORWAY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. NORWAY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 112. POLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 113. POLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. POLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 115. QATAR IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 116. QATAR IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. QATAR IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 127. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 128. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 136. TURKEY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 137. TURKEY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. TURKEY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 145. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 146. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2022
TABLE 147. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeyondSpring Pharmaceuticals Inc.
  • BioLineRx Ltd.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • IQVIA Inc.
  • Jazz Pharmaceuticals PLC
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Mirati Therapeutics Inc.
  • Ono Pharmaceutical Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.15 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.62 Billion
Compound Annual Growth Rate14.5%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Global Lung Cancer Drugs Market by Disease (Non-Small Cell Lung Cancer, Small Cell Lung cancer), Molecule (Biologics, Small Molecules), Distribution Channel - Forecast 2024-2030 - Product Image

Global Lung Cancer Drugs Market by Disease (Non-Small Cell Lung Cancer, Small Cell Lung cancer), Molecule (Biologics, Small Molecules), Distribution Channel - Forecast 2024-2030

  • Report
  • 186 Pages
  • Global
From
Global Extensive Stage Small Cell Lung Cancer Market by Treatment Modalities (Chemotherapy, Combination Therapies, Immunotherapy), Drug Type (Atezolizumab, Durvalumab, Etoposide), Route of Administration, Distribution Channel - Forecast 2024-2030 - Product Image

Global Extensive Stage Small Cell Lung Cancer Market by Treatment Modalities (Chemotherapy, Combination Therapies, Immunotherapy), Drug Type (Atezolizumab, Durvalumab, Etoposide), Route of Administration, Distribution Channel - Forecast 2024-2030

  • Report
  • 196 Pages
  • Global
From
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2024 - Product Image

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2024

  • Clinical Trials
  • 80 Pages
  • Global
From
Non-Small-Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 - Product Image

Non-Small-Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

  • Report
  • 180 Pages
  • Global
From
EGFR Non-Small Cell Lung Cancer - Pipeline Insight, 2024 - Product Image

EGFR Non-Small Cell Lung Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • 80 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.